Risk of share-value dilution from new share issuances and stock acquisition rights
First written in FY2023. 13 of 14 entries say "Materialised", first in FY2024-Q2. Latest entry: 2026-09-28.
Cuorips moved to the "Worse" side of this theme in 2023, 3 years after the typical company in this theme (2020).
The whole theme swung hardest in 2018: 9 of 9 companies on the "Worse" side.
6 other companies' latest entry also says "Materialised".
- FY2026MaterialisedAnnual report
「The increase of 164,260 in the total number of issued common shares resulted from the exercise of stock acquisition rights.」
A further 164,260 shares were issued through exercises of stock acquisition rights during the fiscal year, increasing capital stock and capital surplus by ¥102.313 million each. Share issuance that could cause dilution continued. - FY2026-H1MaterialisedAnnual report
「Net cash provided by financing activities during the interim consolidated accounting period under review was ¥174.109 million, compared with ¥65.663 million in the same interim period of the previous year. This was mainly attributable to ¥146.750 million of proceeds from the issuance of shares through the exercise of stock acquisition rights.」
During the interim period, 138,350 shares were issued through exercises of stock acquisition rights, increasing capital stock and capital surplus by ¥74.938 million each. A further 12,800 shares were issued by the filing date, and 8,200 Sixth Series Stock Acquisition Rights were granted to 21 employees. - FY2025MaterialisedAnnual report
「The increase of 141,000 in the total number of issued common shares resulted from the exercise of stock acquisition rights.」
A further 141,000 shares were issued through exercises of stock acquisition rights during the fiscal year, increasing capital stock and capital surplus by ¥72.403 million each. Share issuance that could cause dilution continued. - FY2025-H1MaterialisedAnnual report
「Net cash provided by financing activities during the interim consolidated accounting period under review was ¥65.663 million. This was mainly attributable to ¥60.000 million of proceeds from the issuance of shares through the exercise of stock acquisition rights.」
Share issuance through exercise of stock acquisition rights generated ¥60.000 million during the interim consolidated accounting period, continuing capital raising that could cause dilution. - FY2024MaterialisedAnnual report
「The increase of 2,291,750 in the total number of issued common shares resulted from the issuance of 1,700,000 shares through a public offering accompanying the listing, 293,800 shares through a private placement accompanying the over-allotment offering, and 297,950 shares through the exercise of stock acquisition rights.」
Shares were actually issued through a public offering, private placement and exercises of stock acquisition rights, increasing shares outstanding. - FY2024-Q3MaterialisedAnnual report
「The partial exercise of the First Series Stock Acquisition Rights issued on 11 October 2021 and the Third Series Stock Acquisition Rights issued on 12 August 2022 increased capital stock and capital surplus by ¥118.264 million each.」
New shares continued to be issued through partial exercises of stock acquisition rights, with total shares outstanding increasing by 30,000 during the third-quarter period. Capital raising that could cause dilution actually occurred. - FY2024-Q2MaterialisedAnnual report
「The partial exercise of the First Series Stock Acquisition Rights issued on 11 October 2021 and the Third Series Stock Acquisition Rights issued on 12 August 2022 increased capital stock and capital surplus by ¥102.859 million each.」
Partial exercise of stock acquisition rights resulted in actual share issuance and increases in capital stock and capital surplus. The company also disclosed a 20,000-share increase from an exercise on 4 October in the number of shares outstanding as of the filing date. - FY2023First statedAnnual report
「The issuance of these new shares and stock acquisition rights could dilute the per-share value of our stock.」
The company cites the possibility of capital increases accompanying expanded research and development and the issuance of stock acquisition rights to secure personnel.